GlassScriptPhysician profile
Meghan Jo Shackleton
NPI 1700495819
$3,069.92
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $782 · 2023: $669 · 2024: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $548.92 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $540.53 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $437.66 | 2021-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbvie INC. | $428.80 | 2021-2024 | |
| Dexcom, INC. | $135.04 | 2021-2023 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $130.44 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Indivior INC. | $129.41 | 2023-2024 | Sublocade |
| Novo Nordisk INC | $117.22 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.65 | 2021-2024 | Xifaxan |
| Amgen INC. | $59.52 | 2021-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $57.06 | 2021-2022 | |
| Uswm, LLC | $49.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.38 | 2022 | |
| Corcept Therapeutics | $39.14 | 2024 | Korlym |
| Pfizer INC. | $37.05 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.38 | 2021 | |
| Braeburn INC. | $28.09 | 2024 | Brixadi |
| Alkermes, INC. | $26.29 | 2023 | Aristada, Lybalvi |
| Amarin Pharma, INC. | $22.09 | 2021 | |
| Gilead Sciences, INC. | $19.95 | 2023 | |
| Sumitomo Pharma America, INC. | $15.52 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $12.77 | 2023 | Quviviq |
| Organon LLC | $12.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.30 | 2022 | |
| Mylan Specialty L.P. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Shackleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.